Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the interactions of buprenorphine-naloxone, a
medication used to treat opiate (heroin or prescription narcotic) dependence, and medications
used in the treatment of HIV disease including atazanavir (Reyataz), fosamprenavir (Lexiva),
didanosine (Videx), tenofovir (Viread), atazanavir (Reyataz)/ritonavir (Norvir),
fosamprenavir (Lexiva)/ritonavir (Norvir), lamivudine (Epivir), or darunavir (please note
that we have completed drug interaction studies for buprenorphine with atazanavir,
atazanavir/ritonavir, didanosine, tenofovir and lamivudine) at the PI's previous university;
for this CHR application only the studies needed to be completed at UCSF/SFGH will be
discussed) or tuberculosis(TB) (rifampin or rifabutin) medications (note: supplement
application currently pending). Participants are those with opioid dependence who qualify for
buprenorphine/naloxone treatment or they are healthy subjects without opioid dependence who
participate in pharmacokinetics studies of the antiretroviral medications. A total of 160
such individuals will be enrolled in these studies (please note that the studies have been
ongoing at Virginia Commonwealth University for 3 years so that the total number of
participants to be recruited at UCSF/SFGH will be about 50 protocol completers). Participants
take the HIV or tuberculosis medicine(s) for up to 15 days (depending on the medication(s)
administered and ability to schedule blood and urine sampling sessions).
Phase:
Phase 1
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
State University of New York at Buffalo University of Utah